Antisense Inhibition of BRCA1 Expression and Molecular Analysis of Hereditary Tumors Indicate That Functional Inactivation of the p53 DNA Damage Response Pathway Is Required for BRCA-Associated Tumorigenesis

This publication has 16 references indexed in Scilit:

• Piecing Together the p53 Puzzle
  Science, 2000
• Increased frequency ofTP53 mutations inBRCA1 andBRCA2 ovarian tumours
  Genes, Chromosomes and Cancer, 1999
• Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations
  JNCI Journal of the National Cancer Institute, 1999
• p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
  Oncogene, 1998
• Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation
  Nature Genetics, 1997
• The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi Jews
  New England Journal of Medicine, 1997
• BRCA1-p53 relationship in hereditary breast cancer
  International Journal of Oncology, 1997
• A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
  Cell, 1992
• Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome
  Nature Genetics, 1992
• Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma.
  Proceedings of the National Academy of Sciences, 1975